Biblio

Export 14 results:
Author Title Type [ Year(Asc)]
Filters: Author is Doody, Rachelle S and First Letter Of Keyword is A  [Clear All Filters]
2024
A. Neve, Das, B., Wojtowicz, J., Huang, Z., Bullain, S., Watkin, M., Lott, D., Bittner, T., Delmar, P., Klein, G., Hofmann, C., Kerchner, G. A., Smith, J., Baudler, M., Fontoura, P., and Doody, R. S., Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)., J Alzheimers Dis, vol. 101, no. 1, pp. 353-367, 2024.
A. Neve, Das, B., Wojtowicz, J., Huang, Z., Bullain, S., Watkin, M., Lott, D., Bittner, T., Delmar, P., Klein, G., Hofmann, C., Kerchner, G. A., Smith, J., Baudler, M., Fontoura, P., and Doody, R. S., Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)., J Alzheimers Dis, vol. 101, no. 1, pp. 353-367, 2024.
A. Neve, Das, B., Wojtowicz, J., Huang, Z., Bullain, S., Watkin, M., Lott, D., Bittner, T., Delmar, P., Klein, G., Hofmann, C., Kerchner, G. A., Smith, J., Baudler, M., Fontoura, P., and Doody, R. S., Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)., J Alzheimers Dis, vol. 101, no. 1, pp. 353-367, 2024.
A. Neve, Das, B., Wojtowicz, J., Huang, Z., Bullain, S., Watkin, M., Lott, D., Bittner, T., Delmar, P., Klein, G., Hofmann, C., Kerchner, G. A., Smith, J., Baudler, M., Fontoura, P., and Doody, R. S., Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)., J Alzheimers Dis, vol. 101, no. 1, pp. 353-367, 2024.
2014
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.